|
Patent landscape, scope, and claims: |
United States Patent 8,178,541: Scope, Claim Boundaries, and US Landscape
What does US 8,178,541 claim at the core?
US Drug Patent 8,178,541 is directed to a combination: (1) a specific xanthine derivative defined by Formula (I), plus (2) one or more selected standard-of-care metabolic or cardiometabolic agents. The claims cover both pharmaceutical compositions and methods of treatment.
The pivotal patentable element is the “first compound of formula (I)”, constrained by three substituent definitions:
- R1 = 4-methyl-2-quinazolinylmethyl
- R2 = methyl
- R3 = 2-butyn-1-yl (or an enantiomeric mixture, or a salt)
The claims repeatedly crystallize this into the same explicit chemical identity:
- 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
- and physiologically acceptable salts (inorganic or organic acids/bases), including inorganic/organic acid salts as explicitly recited.
What is the protected formulation scope?
Across the independent claim set, the scope is built around three layers:
1) Molecule constraint
- The first compound must meet Formula (I) substituent restrictions, or be an enantiomer mixture, or a salt.
2) Disease target pairing
- Type 2 diabetes mellitus and/or obesity (in method claims).
- Cardiometabolic co-therapy is allowed broadly: anti-diabetics, lipid lowering agents, obesity drugs, and high blood pressure drugs.
3) Optional co-formulation
- Pharmaceutical compositions may include inert carriers and/or diluents.
Claim backbone (high-level)
- Composition claims (Claim 1 and dependent structure): compound (I) + one or more other therapeutic agents chosen from enumerated sets.
- Method claims (Claim 15 and dependent structure): administering compound (I) + one or more other therapeutic agents from the same enumerated sets.
- Narrower “combination literal” claims: specify the first compound explicitly and call out particular partner drugs (e.g., metformin, pioglitazone, sulphonylureas).
What exact therapeutic partner classes are within scope?
The claims contain broad lists. Functionally, the patent covers combination therapy where the partner is selected from the following categories.
A. Antidiabetics (enumerated in the claims)
Antidiabetic partners listed in Claims 2, 16, 29, 30, 35, 39, 40, 41, 43 include:
- Metformin
- Sulphonylureas: glibenclamide, tolbutamide, glimepriride
- Meglitinides: nateglinide, repaglinide
- Thiazolidinediones (TZDs): rosiglitazone, pioglitazone
- PPAR-gamma agonists or antagonists
- PPAR-gamma/alpha modulators
- Alpha-glucosidase inhibitors: acarbose, voglibose
- Other DPPIV inhibitors (explicitly “different from the first compound of formula I”)
- Alpha2 antagonist
- Insulin
- GLP-1
- Exendin-4
- Amylin
- SGLT2 inhibitors
- Pathway inhibitors:
- protein tyrosine phosphatase 1 inhibitor
- glucose-6-phosphatase inhibitor
- fructose-1,6-bisphosphatase inhibitor
- glycogen phosphorylase inhibitor
- glucagon receptor antagonist
- phosphoenolpyruvate carboxykinase inhibitor
- glycogen synthase kinase inhibitor
- pyruvate dehydrokinase inhibitor
B. Lipid lowering agents
Lipid partners listed in Claims 6, 20, 29, 30, 35 include:
- HMG-CoA-reductase inhibitors (explicit examples in Claim 7: simvastatin, atorvastatin)
- Bezafibrate, fenofibrate (explicit examples in Claims 8 and 22)
- Nicotinic acid
- PPAR-alpha agonist
- PPAR-delta agonist(s)
- ACAT inhibitor
- Cholesterol resorption inhibitor
- Bile acid-binding substance
- Inhibitor of ileac bile acid transport
- HDL-raising compound
- Inhibitor of CETP
- Regulator of ABC1
- Ezetimibe is explicitly named as the cholesterol resorption inhibitor (Claim 9 and Claim 23)
C. Obesity actives
Obesity partners listed in Claims 10, 24, 35, 36 include:
- sibutramine
- tetrahydrolipostatin
- dexfenfluramine
- axokine
- cannabinoid1 receptor antagonist
- MCH-1 receptor antagonist
- MC4 receptor agonist
- NPY5 or NPY2 antagonist
- β3-agonist
- 5HT2c receptor agonist
D. High blood pressure drugs
High blood pressure partners listed in Claims 11, 25, 35, 38 include:
- AII antagonist
- ACE inhibitor
- Diuretic
- β-blocker
How is the scope divided between “composition” and “method”?
Composition claims
- Claim 1: Composition containing the formula (I) compound plus one or more therapeutic agents from the combined enumerated sets (antidiabetics, lipid lowering agents, obesity actives, hypertension drugs), optionally with carriers/diluents.
- Claims 31-33 and 40-48 include additional composition-specific narrowing where the partner is limited to antidiabetics or explicitly named combinations.
Method claims
- Claim 15: Method of treating type II diabetes mellitus or obesity by administering the formula (I) compound plus one or more other therapeutic agents from the enumerated lists.
- Dependent method claims narrow the partner class (sulphonylurea, TZD, alpha-glucosidase inhibitor; lipid-lowering; obesity actives; hypertension drugs).
- Literal-species method claims cover the explicit structure of the first compound and specific partner sets.
What are the highest-value “narrowing” claim points investors and competitors will care about?
The claim set uses two common strategies:
1) Broad class coverage via enumerated therapeutic lists
2) Narrow literal species coverage via explicit molecule + explicit named co-therapies
Key narrowing nodes include:
1) Explicit first-compound identity
Claims 12, 26, 33, 34, 35-39, 40, 41, 43-48 lock in the exact structure:
- 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
- or its salts.
This reduces freedom for design-arounds that attempt to shift substituent identity away from the defined formula.
2) Salt coverage
Claims 13-14 and 27-28 cover physiologically acceptable salts, with explicit recitations that include inorganic or organic acids/bases, and specifically acid salts.
3) Named partner drugs
Multiple dependent claims carve out specific partner drugs, creating both:
- stronger infringement hooks for specific combination regimens, and
- clearer evidence boundaries for claim construction.
Named examples:
- Metformin: Claims 44-45 (composition and method)
- Pioglitazone: Claims 46-47
- Sulphonylureas: glibenclamide, tolbutamide, glimepriride (Claim 3)
- Rosiglitazone/pioglitazone: Claim 4
- Acarbose/voglibose: Claim 5
- Simvastatin/atorvastatin: Claim 7
- Bezafibrate/fenofibrate: Claims 8 and 22
- Ezetimibe: Claim 9 and 23
- Obesity drugs (e.g., sibutramine, β3-agonist, 5HT2c receptor agonist): Claims 10 and 24
- Antihypertensives (AII antagonist, ACE inhibitor, diuretic, β-blocker): Claims 11 and 25
What is the practical claim boundary for combination selection?
Because the claims require:
- the first compound to be the formula (I) xanthine derivative (or salts), and
- the partner to be one or more of the enumerated drug types,
competitors face two primary freedom points:
1) Avoid the first compound
- If a competitor’s candidate is not within the Formula (I) substituent pattern, it is outside the claim’s “molecule gate.”
2) Avoid the listed partner classes
- If the combination partner is not one of the enumerated categories or examples, it may not meet claim limitations.
- Claims also allow “one or more other therapeutic agents selected from” broad enumerations, so replacing a partner within the same drug class may still land within the list unless the substitute is outside those enumerations.
How broad is “therapeutic purpose” within the same combination claims?
The claims use disease framing:
- Type 2 diabetes mellitus and/or obesity for method claims (e.g., Claims 15 and 35-39).
- Yet within Claim 1, the composition can include partners from multiple therapeutic domains (antidiabetics, lipid-lowering, obesity actives, hypertension drugs). This means the composition claim’s partner scope is not limited to only diabetes drugs even when the method claim is.
US patent landscape: what can be concluded from the claim text alone?
The user-provided text includes only the claim set. It does not include:
- the patent’s publication number (US application publication),
- assignee/applicant,
- filing date, priority date,
- number of family members,
- prosecution history,
- citations (e.g., WO/EP equivalents),
- expiration/term data,
- or related patents that would allow mapping freedom-to-operate across active ingredients and combination regimens.
Because the prompt requires a “patent landscape” for the US, such landscape depends on bibliographic and legal-status data that is not present in the claim excerpt.
Per constraints, no additional conclusions are produced without verifiable record facts.
Key Claim Map (Claims 1-48 grouped by scope)
Independent claims and what they cover
- Claim 1 (Composition): Formula (I) xanthine derivative + one or more other therapeutic agents from:
- antidiabetics, lipid lowering agents, obesity actives, high blood pressure drugs
- optional carriers/diluents
- Claim 15 (Method): Treat type II diabetes mellitus or obesity by administering:
- Formula (I) compound + one or more other therapeutic agents from the same enumerated set
- Claim 31 (Composition): Formula (I) compound + antidiabetic limited list (metformin, sulphonylureas, nateglinide, repaglinide, TZDs, PPAR-gamma agonists, alpha-glucosidase inhibitors, alpha2 antagonists, insulin, GLP-1, exendin-4, amylin)
- Claim 32 (Method): Treat type II diabetes mellitus by administering:
- Formula (I) compound + antidiabetic limited list (subset)
- Other dependent and literal-species claims tighten partner drugs and/or therapeutic context.
Dependent claims that materially narrow partner drug
- Sulphonylureas: Claim 3, 17, 41, 48
- TZDs: Claim 4, 18, 42, 47
- Alpha-glucosidase inhibitors: Claim 5, 19
- HMG-CoA reductase inhibitors: Claim 7, 21
- Bezafibrate/fenofibrate: Claims 8, 22
- Ezetimibe: Claims 9, 23
- Obesity actives: Claims 10, 24
- High blood pressure drugs: Claims 11, 25
- Explicit first compound: Claims 12, 26, 33, 34, 36-39
Design-around pressure points (based on claim structure)
- Structural constraint on Formula (I) is the primary gate. Any real avoidance strategy must address whether the candidate is literally within the defined substituent scheme for R1/R2/R3 or within equivalent structures as construed.
- Salt forms are claimed broadly, so switching counterion is not a clean workaround if the salt qualifies as “physiologically acceptable.”
- Combination flexibility is high for partners because claims list multiple drug families and allow “one or more” agents. Avoidance therefore requires partner selection outside the enumerated lists.
Key Takeaways
- US 8,178,541 claims combination therapy built around a single constrained xanthine derivative (Formula (I)) paired with enumerated metabolic and cardiometabolic agents.
- The claim set covers both pharmaceutical compositions and methods for type 2 diabetes mellitus and/or obesity, with broad partner drug lists and multiple dependent claims that lock in specific named drugs (metformin, pioglitazone, glibenclamide/tolbutamide/glimepiride, simvastatin/atorvastatin, ezetimibe, acarbose/voglibose).
- The core freedom-to-operate lever is avoiding the Formula (I) molecule class and, secondarily, avoiding partner drugs that fall inside the enumerated therapeutic lists.
- A full “US patent landscape” (family members, expiration, competing filings, and citation networks) cannot be derived from the provided claim excerpt alone.
FAQs
1) What is the claimed “first compound” identity in US 8,178,541?
The first compound is the xanthine derivative defined by Formula (I) with R1 = 4-methyl-2-quinazolinylmethyl, R2 = methyl, R3 = 2-butyn-1-yl, including enantiomer/mixed enantiomers and physiologically acceptable salts; it is also explicitly stated as 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.
2) Do the claims require that the partner drug be for diabetes only?
No. Claim 1 allows partner agents from antidiabetics, lipid lowering agents, obesity actives, and high blood pressure drugs, while the method claims frame treatment for type 2 diabetes and/or obesity.
3) Are salts of the first compound covered?
Yes. The claims include physiologically acceptable salts with inorganic or organic acids/bases, and explicitly include acid salts.
4) Which named metformin combination claims exist?
Metformin is expressly recited in Claim 44 (composition with the explicit xanthine + metformin) and Claim 45 (method with the explicit xanthine + metformin).
5) Which named TZD combinations exist?
Pioglitazone is explicitly recited in Claims 46-47 (composition and method).
References
[1] United States Patent No. 8,178,541. Claims 1-48 (as provided in the prompt).
More… ↓
⤷ Start Trial
|
